Researchers from the Australian Peter MacCallum Cancer Centre and colleagues, including some from Cylene Pharmaceuticals Inc., have reported that by inhibiting RNA Polymerase I with their preclinical compound CX-5461, they were able to activate p53 specifically in cancer cells – a feat that researchers have been trying to achieve "for many years," Cylene CEO William Rice told BioWorld Today.